Table 2.

Major health care services and resource utilization

Characteristics	All (n = 138)	Health center (n = 44)	Hospital (n = 94)	P-value*
Antibiotics; n (%)	85(61.59)	43(97.73)	42(44.68)	< 0.001**
Co-trimoxazole suspension 40 mg/200 mg per 5 ml	37(26.81)	36(81.82)	1(1.06)	< 0.001**
Ampicillin injection 1 g	27(19.57)	0(0.0)	27(28.72)	< 0.001**
Gentamicin injection 1 vial 80 mg	14(10.14)	0(0.0)	14(14.89)	0.005**
Metronidazole syrup 125 mg 100 ml	14(10.14)	10(22.73)	4(4.26)	0.002****
Amoxicillin syrup 125 mg/5 ml	10(7.25)	4(9.09)	6(6.38)	0.726****
Cefotaxime injection 1 g IM/IV	7(5.07)	0(0.0)	7(7.45)	0.097****
Metronidazole injection .500 mg/100 ml	7(5.07)	0(0.0)	7(7.45)	0.097****
Laboratory tests (%)	93(67.39)	30(68.18)	63(67.21)	0.892**
Full blood count	60(43.48)	0(0.0)	60(63.83)	< 0.001**
C-reactive protein (CRP)	56(40.58)	0(0.0)	56(59.57)	< 0.001**
Thick blood smear	56(40.58)	5(11.36)	51(54.26)	< 0.001**
Stool microscopy	33(23.91)	24(54.55)	9(9.57)	< 0.001**
Malaria rapid test	15(10.87)	15(34.09)	0(0.0)	< 0.001**
Ringer lactate 500 ml	60(43.48)	0(0.0)	60(63.83)	< 0.001**
Paracetamol syrup 120 mg/5 ml	28(20.29)	27(61.36)	1(1.06)	< 0.001**
ORS	37(26.81)	33(75.00)	4(4.26)	< 0.001**
Zinc sulfate 20 mg tablet	41(29.71)	32(72.73)	9(9.57)	< 0.001**
Length of stay (day) a; mean (SD), median	8.90 (3.6),9.0	n/a	8.90 (3.6),9.0	n/a
Treatment before visit or admission; n (%)	51(36.96)	6 (13.64)	45 (47.87)	< 0.001**
Treatment after admission/visit; n (%)	7 (5.07)	0 (0.0)	7 (7.45)	0.097****
Caregiver’s time loss (day); mean (SD), median	7.45 (8.91),4	2.72 (1.89),2	9.66 (9.98),5	< 0.001***

n/a not applicable, SD standard deviation, ORS Oral rehydration salts

^*To compare between health center (CMC Buyenzi) and hospital (Prince Regent Charles), a p-value < 0.05 was used as statistical significance

^** Chi-square

^*** Mann-Whitney U test

^**** Fisher’s Exact test

^afor inpatients